Rx/Reimbursement Adult Incontinence in the Czech Republic

Rx/reimbursement adult incontinence saw volume and value growth in the Czech Republic in 2024. The growth of the category is being fuelled not just by the ageing population but also by more information about Rx rights and reimbursements via magazines and pharmacies. Since 1 January 2024, the VAT rate has been reduced from 15% to 12% and this change has been reflected in the price of incontinence products. Patient co-payment remained unchanged.

The Rx/Reimbursement adult incontinence in Czech Republic report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2020-2024, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, distribution or pricing issues. Forecasts to 2029 illustrate how the market is set to change.

Data coverage: Market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Rx/Reimbursement adult incontinence market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.